3:30pm Chair Introduction

Samik Basu, Chief Scientific Officer, Cabaletta Bio

3:35pm Presentation: Taming Autoimmunity with CAR T

• Introduction to Kyverna
• CAR T Approach and differentiation
• Getting to the clinic and the promise of CAR T for Autoimmunity

Karen Walker, Chief Technical Officer, Kyverna Therapeutics

3:50pm Presentation: Cell-Based Therapies for T cell Mediated Disease

• the challenge of T cell targeting
•  Building robust, modular cell-based therapies for T cell mediated autoimmune disease and T cell malignancies
•  Combining machine learning and synthetic biology to optimize T cell modifying cell therapies

Cameron Gardner, Director of Research, Jura Bio

4:05pm Presentation: Developing CAR Tregs as Living Therapeutics for Type 1 Diabetes

• Using CRISPR-Cas9 and homology-directed repair to modify human Tregs with precision
• Assessing trafficking of engineered cells in humanized mouse models
• Enhancing human Treg expansion with new modulators

Leonardo M.R. Ferreira, Assistant Professor of Microbiology and Immunology, Medical University of South Carolina

4:20pm Presentation: Engineered T cell Therapy for Autoimmune Disease

• Cellular therapy has the potential to deliver durable complete responses for treatment refractory autoimmune disease.
• Precision ablation of B cells may be sufficient to reset the immune system to a normal state.

Gwen Binder, President, Science & Technology, Cabaletta Bio

4:35pm Closing Panel with Q&A

With all session participants